|
Combination of Paclitaxel and Ifosfamide in Anthracycline Resistant Advanced Breast Cancer. |
|
|
Honoraria - Amgen; Gilead Sciences; Lilly; Pfizer; Taiho Pharmaceutical |
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Five Prime Therapeutics; Lilly; MSD Oncology; Roche/Genentech; Sanofi |
Research Funding - Janssen-Cilag (Inst); Lilly (Inst); Merck Serono (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck Serono; MSD; Sanofi |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Five Prime Therapeutics; Lilly; Merrimack; MSD; Novartis; Ono Pharmaceutical; PharmaEngine; Syncope, Taiwan; TTY Biopharm |
Research Funding - GlaxoSmithKline (Inst); Merck Serono (Inst); Novartis (Inst); Polaris (Inst); TTY Biopharm (Inst) |
Patents, Royalties, Other Intellectual Property - anti-alpha-enolase (ENO-1) monoclonal antibody to HuniLife Technology, Taiwan |
|
|
Consulting or Advisory Role - Lilly/ImClone; Novartis; Ono Pharmaceutical; Roche/Genentech; Taiho Pharmaceutical |
Research Funding - LSK Biopharma |
|
|
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Serono; Takeda; Yakult Honsha |
Consulting or Advisory Role - Bayer Yakuhin; Lilly; Merck Serono; Ono Pharmaceutical; Takara Bio |
Research Funding - Chugai Pharma (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Yakult Honsha (Inst) |
|
|
Consulting or Advisory Role - Ono Pharmaceutical |
Research Funding - MSD Oncology; Ono Pharmaceutical; Shionogi |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Celltrion; Lilly; Merck Serono; MSD; Quintiles; Taiho Pharmaceutical |
Speakers' Bureau - Foundation Medicine; Lilly; Merck Serono |
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck Serono; MSD; Taiho Pharmaceutical |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Daiichi Sankyo; Lilly; MedImmune; MSD Oncology; Ono Pharmaceutical; orient EuroPharma; TTY Biopharm |
|
|
Consulting or Advisory Role - Alexion Pharmaceuticals; Amgen; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Genentech; Neon Therapeutics |
Research Funding - ARMO BioSciences (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Merck (Inst) |
|
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Merck |
Research Funding - Aduro Biotech; Bristol-Myers Squibb; Merck |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb; GlaxoSmithKline |
|
Maria Jesus Jimenez-Exposito |
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Lilly; Pfizer |
Research Funding - Amgen; Bayer; Boehringer Ingelheim; Genentech; Lilly; Roche |
|
|
Honoraria - Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Shionogi; Taiho Pharmaceutical; Yakult Honsha |
Research Funding - Bristol-Myers Squibb (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst) |